Biophytis (ALBPS.PA EURONEXT) up 31.40% pre-market 29 Jan 2026: heavy volume flags active interest
ALBPS.PA stock surged 31.40% in pre-market trading on 29 Jan 2026, trading at EUR 0.077 on EURONEXT with volume at 21,133,836.00 shares. The move follows heavy intraday activity and a wide intraday range from EUR 0.0698 to EUR 0.1098. Pre-market volume is roughly 85.17x the average, making ALBPS.PA a high-volume mover for Europe healthcare sessions. We summarise what drove the move, the fundamental picture, technical signals, and where analysts and our models place possible targets
ALBPS.PA stock: Pre-market price and volume action
Biophytis S.A. (ALBPS.PA) opened pre-market at EUR 0.0698 and is trading at EUR 0.077 with a +31.40% change versus the previous close of EUR 0.0586. Reported volume is 21,133,836.00, far above the 50-day average of 248,126.00, indicating outsized retail or block activity.
The intraday band runs from EUR 0.0698 low to EUR 0.1098 high. Relative volume of 85.17 supports that this is a true high-volume mover in the pre-market session on EURONEXT, Europe.
ALBPS.PA stock: Clinical pipeline and news drivers
Biophytis focuses on Sarconeos (BIO101) and Macuneos (BIO201) in biopharma and biotechnology. Recent attention comes from trial updates and an upcoming earnings announcement slated for 2026-02-23. Clinical readouts or regulatory milestones typically shift liquidity and share moves in ALBPS.PA.
Investors should track official releases on the company website and corporate LinkedIn for confirmation before trading. See Biophytis sources: company site and LinkedIn.
ALBPS.PA stock: Fundamentals and valuation
At EUR 0.077, Biophytis carries a market cap of EUR 1,788,769.00 and 23,230,769.00 shares outstanding. Trailing EPS is -0.34 and the reported PE is -0.23, reflecting persistent losses. Cash per share is 0.0627 and the current ratio is 0.35, indicating limited near-term liquidity.
Enterprise value sits near EUR 8,353,769.00, and free cash flow per share is negative. These metrics frame ALBPS.PA stock as high risk with a small-cap capital structure sensitive to financing and clinical news.
ALBPS.PA stock: Technicals and trading signals
Momentum indicators show the stock is oversold but volatile. RSI is 23.81 and MFI is 6.94, both in oversold territory. ADX at 57.88 signals a strong trend while MACD is flat near -0.01.
Short-term averages: 50-day average is EUR 0.071 and 200-day average is EUR 0.129. Bollinger Bands run roughly EUR 0.060–0.090, so the pre-market spike pierced the upper band. Heavy volume and a low float amplify intraday moves for ALBPS.PA stock.
ALBPS.PA stock: Meyka AI grade and model forecast
Meyka AI rates ALBPS.PA with a score out of 100: 67.42 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a 1-year price of EUR 3.651. Versus the current price of EUR 0.077, that model implies a theoretical upside of +4,644.18%. Forecasts are model-based projections and not guarantees. Use model output alongside clinical milestones and liquidity checks before taking positions.
ALBPS.PA stock: Trading strategy and key risks
Given the low market cap and high pre-market volume, a short-term trading plan is prudent. We set a conservative short-term price target at EUR 0.15 (implied upside +94.81%) and a conditional 12-month target at EUR 0.40 (implied upside +419.48%) tied to positive clinical progress.
Key risks include continued cash burn, thin float, negative operating cash flow, and the lack of institutional coverage. For investors considering ALBPS.PA stock, size positions appropriately and confirm filings and press releases before trading. For the Meyka page on this ticker, see internal data at ALBPS.PA on Meyka.
Final Thoughts
ALBPS.PA stock is a high-volume mover in the pre-market session on 29 Jan 2026, trading at EUR 0.077 with 21,133,836.00 shares changing hands. The immediate catalyst appears tied to clinical pipeline focus and elevated speculative activity. Fundamental ratios show negative EPS (-0.34) and a constrained liquidity profile, so price swings can be sharp. Short-term traders may target EUR 0.15 while monitoring order flow and announcements. Longer-term scenarios depend on clinical outcomes; a successful milestone could push price toward the prior year high near EUR 0.404.
Meyka AI’s forecast model projects EUR 3.651 in one year, a model-based view that implies very large upside versus EUR 0.077 today. Forecasts are projections and not guarantees. We recommend verifying company releases and balancing position size to the company’s small market cap and volatile technicals. As an AI-powered market analysis platform, Meyka AI provides these metrics for context, not investment advice.
FAQs
Why did ALBPS.PA stock jump pre-market today?
ALBPS.PA stock rose pre-market on large volume tied to clinical updates and increased speculative trading. Low float and news around BIO101 can magnify moves. Confirm with company filings before trading.
What are the main risks for ALBPS.PA stock?
Key risks include negative EPS, tight cash runway, thin liquidity, and trial or regulatory setbacks. ALBPS.PA stock moves can be volatile and sensitive to single announcements.
What are realistic price targets for ALBPS.PA stock?
A conservative short-term target is EUR 0.15 and a conditional 12-month target is EUR 0.40, tied to positive clinical data. Use targets only as scenario guides.
How should I use Meyka AI’s forecast for ALBPS.PA stock?
Meyka AI’s forecast offers a model-based scenario. Treat the EUR 3.651 projection as one data point, verify fundamentals and news flow, and size positions to the stock’s high volatility.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
